AIM: To assess the efficacy and tolerability of thalidomide in pediatric Crohn's disease (CD). METHODS: Six patients with refractory CD received thalidomide at an initial dose of 2 mg/kg per day for one month, then increased to 3 mg/kg per day or decreased to 1 mg/kg per day, and again further reduced to 0.5 mg/kg per day, according to the individual patient's response to the drug. RESULTS: Remission was achieved within three months. Dramatic clinical improvement was demonstrated after thalidomide treatment. Endoscopic and pathological improvements were also observed after thalidomide treatment, which was well tolerated by all patients. CONCLUSION: Thalidomide is a useful drug for pediatric refractory CD.
AIM: To assess the efficacy and tolerability of thalidomide in pediatric Crohn's disease (CD). METHODS: Six patients with refractory CD received thalidomide at an initial dose of 2 mg/kg per day for one month, then increased to 3 mg/kg per day or decreased to 1 mg/kg per day, and again further reduced to 0.5 mg/kg per day, according to the individual patient's response to the drug. RESULTS: Remission was achieved within three months. Dramatic clinical improvement was demonstrated after thalidomide treatment. Endoscopic and pathological improvements were also observed after thalidomide treatment, which was well tolerated by all patients. CONCLUSION:Thalidomide is a useful drug for pediatric refractory CD.
Authors: H Wada; K Saito; T Kanda; I Kobayashi; H Fujii; S Fujigaki; N Maekawa; H Takatsu; H Fujiwara; K Sekikawa; M Seishima Journal: Circulation Date: 2001-02-06 Impact factor: 29.690
Authors: G Kaplan; S Thomas; D S Fierer; K Mulligan; P A Haslett; W J Fessel; L G Smith; K A Kook; D Stirling; M Schambelan Journal: AIDS Res Hum Retroviruses Date: 2000-09-20 Impact factor: 2.205
Authors: Juan B De Sanctis; Michael Mijares; Alírica Suárez; Reinaldo Compagnone; Jenny Garmendia; Dolores Moreno; Margarita Salazar-Bookaman Journal: Recent Pat Inflamm Allergy Drug Discov Date: 2010-06
Authors: K Dredge; J B Marriott; C D Macdonald; H-W Man; R Chen; G W Muller; D Stirling; A G Dalgleish Journal: Br J Cancer Date: 2002-11-04 Impact factor: 7.640